TSHA - Company ID 0001806310
The table below shows Taysha Gene Therapies, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M | -$30.73M |
| Capital expenditure | $738.00K | $374.00K | $3.87M | $20.62M | $15.30M | $82.00K |
| Investing cash flow | -$604.00K | -$363.00K | -$7.35M | -$24.93M | -$21.55M | -$9.08M |
| Dividends paid | - | - | - |
Taysha Gene Therapies, Inc. reported operating cash flow of -$93.09M for fiscal year 2025. That is down 14.6% from -$81.22M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$30.73M (FY 2020) to -$93.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $274.59M | $76.68M | $136.39M | $52.10M | $39.08M | $291.06M |